Ouro Fino Saúde Animal Participações S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 04, 2022 at 05:04 pm EDT
Share
Ouro Fino Saúde Animal Participações S.A. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was BRL 235.31 million compared to BRL 230.98 million a year ago. Net income was BRL 23.55 million compared to BRL 31.98 million a year ago. Basic earnings per share from continuing operations was BRL 0.43794 compared to BRL 0.59284 a year ago. Diluted earnings per share from continuing operations was BRL 0.43794 compared to BRL 0.59284 a year ago.
For the six months, sales was BRL 437.62 million compared to BRL 399.77 million a year ago. Net income was BRL 39.54 million compared to BRL 41.47 million a year ago. Basic earnings per share from continuing operations was BRL 0.73542 compared to BRL 0.76876 a year ago. Diluted earnings per share from continuing operations was BRL 0.73542 compared to BRL 0.76876 a year ago.
Ouro Fino Saude Animal Participacoes S.A., also known as Ourofino, is a Brazil-based company engaged in the animal health market business sector in Latin America. The Company manufactures veterinary products using scientific technology in the Company's laboratories. The Company's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
OURO FINO SAÚDE ANIMAL PARTICIPAÇÕES S.A. 
